Compare PGEN & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PGEN | VERA |
|---|---|---|
| Founded | 1998 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | N/A | 2021 |
| Metric | PGEN | VERA |
|---|---|---|
| Price | $4.20 | $50.88 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | $7.67 | ★ $76.60 |
| AVG Volume (30 Days) | ★ 5.0M | 1.8M |
| Earning Date | 11-13-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $6,309,000.00 | N/A |
| Revenue This Year | $342.78 | N/A |
| Revenue Next Year | $478.46 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 59.20 | N/A |
| 52 Week Low | $0.76 | $18.53 |
| 52 Week High | $5.23 | $56.05 |
| Indicator | PGEN | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 54.86 | 67.76 |
| Support Level | $4.05 | $47.22 |
| Resistance Level | $4.53 | $56.05 |
| Average True Range (ATR) | 0.29 | 2.61 |
| MACD | 0.05 | -0.17 |
| Stochastic Oscillator | 69.99 | 61.79 |
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.